Skip to content
Home
About MedNet
Live Programs
Webcasts
Contact
Log in/Registration
Search
Search
Close
Home
About MedNet
Live Programs
Webcasts
Contact
Log in/Registration
×
Home
About MedNet
Live Programs
Webcasts
Contact
Log in/Registration
0
0
Sub-Total:
$
0.00
No products in the cart.
100% Secure Checkout!
Home
/
Specialty
/
Cardiology
/ Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes
Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes
Complimentary
Categories:
Activity Type
,
ANCC
,
Cardiology
,
CME
,
Credit Type
,
Endocrinology
,
Family Medicine
,
Nurse
,
Nurse Practitioner
,
Online Activity
,
Physician
,
Physician Assistant
,
Profession
Related products
New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
Read more
Glaucoma: Sustained-release Drug Delivery System, Topical Agents, and Emerging 3D Visualization Technologies
Read more
New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases
Read more
Advances in the Understanding of Etiology, Evaluation, and Management of Neurotrophic Keratitis
Read more
Scroll To Top